AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04230122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study NCT04230122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT04663685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Participants received two 1-on-1 exercise sessions per week to start. Each session lasted 30 minutes. As progress was made, participants were encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises were aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift \& carry and calf raise.
Study NCT04663685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Participants received a nutrition education booklet and had access to five online videos that correspond to key topics in the booklet (reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day). Participants attended three 60-minute nutrition Q\&A sessions led by a dietitian, where the group reviewed content from the booklet and videos, and discussed personalized strategies to increase protein intake.
Study NCT03764280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Daily Injections: Slow acting insulin and Rapid acting insulin
Description: Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
Study NCT04195061 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiopulmonary exercise test (CPET)
Description: CPET studies will be performed in the Cardiovascular Performance Program exercise lab at MGH. Subjects will undergo CPET on an upright cycle ergometer with continual measurement of metabolic gas exchange via a commercially available metabolic cart as well as heart rate and blood pressure. Exercise will proceed according to a maximal effort clinical protocol. Subjects will then undergo a standardized 30-min work load on the upright cycle ergometer based on the results of the maximal effort clinical protocol.
Study NCT01921803 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation
Study NCT01701804 — intervention group
Intervention type: DRUG
Intervention: Chuna herbal medicine
Description: 120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
Study NCT01701804 — intervention group
Intervention type: PROCEDURE
Intervention: Chuna manual therapy
Description: A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
Study NCT01701804 — intervention group
Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10\~20 acupoints once a week for 16 weeks.
Study NCT01701804 — intervention group
Intervention type: PROCEDURE
Intervention: Bee-venom pharmacoacupuncture
Description: Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
Study NCT01124318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactofiltrum
Description: Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
Study NCT01124318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets 3 times a day before meals during 21 days
Study NCT05796700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation
Study NCT02589470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMETE
Description: Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
Study NCT01976481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sunbed exposure
Description: exposure to sunbed ultraviolet radiation
Study NCT02550743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study NCT02550743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02550743 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT01077323 — intervention group
Intervention type: DRUG
Intervention: exenatide
Description: subcutaneous injection, dosing according to normal clinical practice
Study NCT01077323 — intervention group
Intervention type: DRUG
Intervention: Other antidiabetic therapies
Description: Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
Study NCT01077323 — intervention group
Intervention type: OTHER
Intervention: No diabetes therapy
Description: Subjects not diagnosed with diabetes
Study NCT05628701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileorectal anastomosis (IRA)
Description: After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))
Study NCT05628701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileorectal anastomosis (IRA)
Description: After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))
Study NCT05628701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileal pouch anal anastomosis (IPAA)
Description: The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).
Study NCT05628701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileal pouch anal anastomosis (IPAA)
Description: The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).
Study NCT05628701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ileostomy
Description: no reconstruction is performed and the patient is left with his/her ileostomy
Study NCT03812900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea alcoholic extract
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
Study NCT03812900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea alcoholic extract
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
Study NCT02500316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
Study NCT00729716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioCart™II
Description: A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
Study NCT00729716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
Study NCT01246895 — intervention group
Intervention type: DEVICE
Intervention: Microfracture with BST-CarGel
Study NCT01246895 — intervention group
Intervention type: DEVICE
Intervention: Microfracture without BST-CarGel
Study NCT02298348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
Study NCT02298348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
Study NCT02298348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan
Description: 0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
Study NCT01124747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral
Study NCT01124747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Labeled ASP1585
Description: Oral
Study NCT02436863 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical performance
Description: Two different surgical performances
Study NCT03740269 — intervention group
Intervention type: OTHER
Intervention: oral health educational program
Description: poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
Study NCT01026948 — intervention group
Intervention type: DRUG
Intervention: Dinoprostone
Description: Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
Study NCT01026948 — intervention group
Intervention type: DEVICE
Intervention: Monica AN 24
Description: AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
Study NCT03281941 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inhaled capsaicin cough challenge
Study NCT00558987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discipline Video
Description: 1. The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~2. A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers.
Study NCT00558987 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutrition Video
Description: A brief educational video on nutrition information, a topic not related to discipline.
Study NCT03970525 — intervention group
Intervention type: DEVICE
Intervention: Venturi pump
Description: The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.
Study NCT03970525 — intervention group
Intervention type: DEVICE
Intervention: Peristaltic vacuum pump
Description: The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material.
Study NCT01935024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Exercise Regimen
Description: All exercise regimens include a stationary bicycle.
Study NCT00802646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
Study NCT00802646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl/bupivacaine/epinephrine
Description: intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
Study NCT01655225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.
Study NCT01655225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
Study NCT01655225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
Study NCT01655225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 administered IV once on Day 1 every 21 days
Study NCT01655225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 administered IV once on Day 1 every 21 days
Study NCT01655225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT01655225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally
Study NCT01660867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% saline + oral placebo
Description: nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
Study NCT01660867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline + oral dexamethasone
Description: nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
Study NCT01660867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline + oral dexamethasone
Description: nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
Study NCT02721056 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NBTXR3, IL or IA injection + SBRT
Description: Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).
Study NCT01157611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentoring program
Description: mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
Study NCT02434874 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: StimGuard Sacral Nerve Stimulator System
Description: The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
Study NCT02434874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimGuard Sacral Nerve Stimulator System
Description: The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
Study NCT01676701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tabalumab Auto-Injector
Description: Administered SC by auto-injector
Study NCT01676701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tabalumab Prefilled Syringe
Description: Administered SC by prefilled syringe
Study NCT03851848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint mobilization (JM)
Description: Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
Study NCT03851848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Description: Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
Study NCT03708263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excel V 532nm (KTP) green Laser
Description: Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
Study NCT03708263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOTOLASE PLV 585 nm yellow laser
Description: Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
Study NCT02825914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein glycomacropeptide (CGMP)
Study NCT02825914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04443647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray
Study NCT04443647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study NCT00810199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: tocilizumab 8 mg IV every 4 weeks.
Study NCT00810199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: tocilizumab 8 mg IV every 4 weeks.
Study NCT00810199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Approximately 15-17 mg methotrexate capsule orally once a week.
Study NCT00810199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching methotrexate capsule taken orally once a week.
Study NCT01448252 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)
Description: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
Study NCT01448252 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: T cell vaccination
Description: Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
Study NCT00888888 — intervention group
Intervention type: PROCEDURE
Intervention: Right hemicolectomy with or without primary anastomosis
Description: During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy